切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2012, Vol. 06 ›› Issue (01) : 24 -30. doi: 10.3877/cma. j. issn.1674-0807.2012.01.004

论著

同时转移性乳腺癌外科治疗预后因素分析
秦允生1, 黄子一2,(), 黄楚坚1, 吴俊东2, 许强周1   
  1. 1.515031 汕头,汕头大学医学院肿瘤医院胸外科
    2.515031 汕头,汕头大学医学院肿瘤医院乳腺科
  • 收稿日期:2011-11-22 出版日期:2012-02-01
  • 通信作者: 黄子一

Analysis of prognostic factors for synchronous metastatic breast cancer patients treated by surgery

Yun-sheng QIN1, Zi-yi HUANG1,(), Chu-jian HUANG1, Jun-dong WU1, Qiangzhou XU1   

  1. 1.Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, Shantou 515031,China
  • Received:2011-11-22 Published:2012-02-01
  • Corresponding author: Zi-yi HUANG
引用本文:

秦允生, 黄子一, 黄楚坚, 吴俊东, 许强周. 同时转移性乳腺癌外科治疗预后因素分析[J/OL]. 中华乳腺病杂志(电子版), 2012, 06(01): 24-30.

Yun-sheng QIN, Zi-yi HUANG, Chu-jian HUANG, Jun-dong WU, Qiangzhou XU. Analysis of prognostic factors for synchronous metastatic breast cancer patients treated by surgery[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2012, 06(01): 24-30.

目的

探讨影响同时转移性乳腺癌(synchronous metastatic breast cancer,sMBC)外科治疗预后的因素。

方法

分析2000年1月至2010年12月本院收治sMBC患者269 例的临床资料,其中手术治疗40 例,非手术治疗229 例作为对照组,采用Logrank 检验比较手术治疗组和对照组的生存率差异,Cox 回归模型分析相关因素对预后的影响。

结果

手术组和对照组的1年生存率为83.8%和71.6%(P=0.018),3年生存率为47.1%和23.5%(P=0.000),5年生存率为22.1%和11.4%(P=0.000),差异均有统计学意义。单因素方差分析显示,雌激素受体阳性和术后化疗是提高sMBC 患者手术疗效的预后因素,多因素方差分析显示术后化疗是影响手术预后的独立因素。

结论

部分经过选择的sMBC 患者进行外科手术治疗能显著延长生存时间,提高生存率。术后化疗是影响手术效果的重要因素。

Objective

To explore the prognostic factors of synchronous metastatic breast cancer (sMBC) patients who underwent surgical treatment.

Methods

The clinical data of 269 sMBC patients admitted into our hospital from January 2000 to December 2010 was collected and analyzed. They included 40 sMBC patients treated by surgery (the surgery group) and 229 sMBC patients receiving non-operative treatment (the control group). Logrank test was used to compare the overall survival (OS) of the patients between the surgery group and the control group, and COX regression model to analyze the prognostic factors of surgical treatment.

Results

The one-year survival of the surgery group and the control group was 83.8% and 71.6%(P=0.018),3-year survival was 47.1% and 23.5%(P=0.000),5-year survival was 22.1% and 11.4% (P = 0.000). All differences were statistically significant. Univariate analysis showed that estrogen receptor-positive and adjuvant chemotherapy were two important factors in improving the prognosis of surgically treated patients. Multivariate analysis showed that adjuvant chemotherapy is an independent factor affecting surgical outcomes.

Conclusion

Surgical treatment for selected sMBC patients can significantly prolong survival time and improve survival rate. Adjuvant chemotherapy is an important factor affecting results of operation.

表1 269 例患者的临床病理特征 [例数(%)]
图1 手术组和非手术组的生存曲线
表2 生存率比较
表3 单因素方差分析结果
表4 多因素方差分析结果
[1]
Khan SA, Stewart AK, Morron M, et al. Does aggressive local therapy improve survival in metastatic breast cancer?[J].Surgery,2002,132(4):620-626.
[2]
Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis[J]. J Clin Oncol,2006,24(18):2743-2749.
[3]
Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data[J]. Ann Surg Oncol,2007,14(8):2187-2194.
[4]
Retsky M, Bonadonna G, Demicheli R, et al. Hypothesis: induced angiogenesis after surgery in premenopausal nodepositive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients[J]. Breast Cancer Res 2004;6:R372-R374.
[5]
Parmar V, Hawaldar RW, Pandey. Surgical removal of primary tumor in women with metastatic breast cancer—Is it really justified? [J]. ASCO breast cancer symposium,2009,323.
[6]
秦允生,黄楚坚,马长春.乳腺癌局限性转移癌的研究进展[J].中华乳腺病杂志:电子版,2009,3(5):56-58.
[7]
秦允生,黄楚坚,黄文河.等.同时性转移性乳腺癌的外科治疗[J].中华内分泌外科杂志,2011,5(6):390-391.
[8]
Gradishar WJ, Bellon JR, Gtadd MA, et al. A 47-year-old woman with a mass in the breast and a solitary lesion in the spine[J]. N Engl J Med,2008,359(13):1382-1391.
[9]
Fields RC, Jeffer DB, Trinkans K, et al. Surgical resection of the primary tumor is assiciated with ingreased long-term survival in patient with stage Ⅳbreast cancer after controlling for site of metastasis[J]. Ann Surg Oncol,2007,14(12):3345-3351.
[10]
Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al. Surgical resection of the primary tumor is associated with improved survival in patients with distant metastatic breast cancer at diagnosis[J]. Eur J Surg Oncol, 2009,35(11):1146-1151.
[11]
Cristofanilli M,Hayes DF,Budd GT,et al. Circulating tumor cells:a novel prognostic factor for newly diagnosed metastatic breast cancer[J]. J Clin Oncol,2005,23(3):1420-1430.
[12]
Dean M,Fojo T,Bates S. Tumour stem cells and drug resistance[J]. Nat Rev Cancer,2005,5(4):275-284.
[13]
Cristofanilli M,Budd GT,Ellis MJ,et al. Circulating tumor cell,disease progression, and survival in metastatic breast cancer[J]. N Engl J Med,2004,351(8):781-791.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 李友, 唐林峰, 杜伟伟, 刘海亮, 余新水, 沈佳宇, 巨积辉. 皮瓣联合掌长肌腱折叠单排三点式固定治疗指背侧创面伴锤状指畸形的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 485-490.
[3] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[4] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[8] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[9] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[10] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[11] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[12] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要